Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/9947
Title: Small cell Carcinomas of the bladder highly express somatostatin receptor type 2A: Impact on prognosis and treatment-a multicenter study of urooncology society, Turkey
Authors: Nese, N.
Kumbaraci, B.S.
Baydar, D.E.
Kilicaslan, I.
Sari, A.A.
Sen, S.
Gonul, I.I.
Keywords: Bladder
Cancer
Small cell carcinoma
Somatostatin receptor
SSTR-2A
somatostatin derivative
somatostatin receptor
somatostatin receptor 1
somatostatin receptor 2A
somatostatin receptor 3
somatostatin receptor 4
somatostatin receptor 5
unclassified drug
somatostatin receptor 2
tumor marker
adult
aged
Article
bladder cancer
bladder small cell carcinoma
cancer prognosis
cancer survival
cancer therapy
clinical article
clinical feature
female
histopathology
human
human tissue
immunohistochemistry
immunoreactivity
male
priority journal
protein expression
small cell carcinoma
transitional cell carcinoma
Turkey (republic)
bladder tumor
clinical trial
metabolism
middle aged
multicenter study
prognosis
very elderly
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Carcinoma, Small Cell
Female
Humans
Immunohistochemistry
Male
Middle Aged
Prognosis
Receptors, Somatostatin
Urinary Bladder Neoplasms
Publisher: Lippincott Williams and Wilkins
Abstract: Small cell carcinoma (SmCC) is a rare and aggressive neuroendocrine carcinoma of the bladder. Neuroendocrine carcinomas expressing somatostatin receptors (SSTR) in other viscera such as lung, pancreas, and gastrointestinal system respond to therapy with somatostatin analogs. In the present study, expressions of SSTRs 1 to 5 including type 2A are investigated by immunohistochemistry (IHC) and their relationship with clinicopathologic factors was evaluated. Hundred primary bladder SmCC cases were collected from 12 centers in Turkey. Forty-three cases were pure SmCC. Other cases had mostly papillary urothelial carcinoma as a second component. The percentage of the SmCC component ranged from 5% to 100%. SSTR-2A expression was membranous, whereas the other receptors showed cytoplasmic staining. The percentages of positive cases for SSTR-1, SSTR-2A, SSTR-3, SSTR-4, and SSTR-5 were 4% (3/75), 61.4% (54/88), 2.4% (2/84), 24.4% (20/82), and 6.25% (5/80), respectively. The percentage of SmCC component was positively correlated with the percentage of SSTR-2A expression (P=0.003) while negatively correlated with patient age (P=0.032). SSTR-2A expression was correlated with survival as a bad prognostic factor (P=0.018). SSTR-1, SSTR-3, SSTR-4, and SSTR-5 expressions did not show any statistical significance with any parameter. In conclusion, although the limited number of cases with adequate term follow-up, SSTR-2A expression could be a prognostic factor and somatostatin analogs therapeutic candidate for SmCCs of the bladder as these tumors show high percentage of SSTR-2A expression. © 2016 Wolters Kluwer Health, Inc. All rights reserved.
URI: https://hdl.handle.net/11499/9947
https://doi.org/10.1097/PAI.0000000000000188
ISSN: 1541-2016
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

5
checked on Nov 23, 2024

WEB OF SCIENCETM
Citations

3
checked on Nov 22, 2024

Page view(s)

46
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.